Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
RESEARCH TOOLSreports
Intra-Cellular Therapies (ITCI) Ownership - Who Owns Intra-Cellular Therapies?
804 Followers
Intra-Cellular Therapies (ITCI) Ownership Overview
32.26% Insiders
32.43% Mutual Funds
19.79% Other Institutional Investors
15.52% Public Companies and
Individual Investors
The ownership structure of Intra-Cellular Therapies (ITCI) stock is a mix of institutional, retail and individual investors. Approximately 52.22% of the company’s stock is owned by Institutional Investors, 32.26% is owned by Insiders and 15.52% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Apr 25, 2024 | Sharon Mates Chairman & Ceo,director | Bought | $345618 |
| Mar 22, 2024 | Rory Riggs Director | Bought | $371200 |
| Feb 28, 2024 | Robert Van Nostrand Director | Sold | $1458650 |
| Nov 08, 2023 | Mark Neumann Evp & Cco | Sold | $2357990 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2023 | Bought | $5299 | |
| Dec 31, 2023 | Bought | $65030 | |
| Dec 31, 2023 | Bought | $208414 | |
| Dec 31, 2023 | Bought | $1790500 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 8,678,649 | Institution | 8.32% | 642,306,812 | |
| 7,866,587 | Institution | 7.54% | 582,206,104 | |
| 5,736,643 | Insider | 5.50% | 424,568,948 | |
| 4,777,566 | Institution | 4.58% | 353,587,660 | |
| 4,645,672 | Institution | 4.45% | 343,826,185 | |
| 3,638,389 | Insider | 3.49% | 269,277,170 | |
| 3,596,205 | Insider | 3.45% | 266,155,132 | |
| 3,596,205 | Insider | 3.45% | 266,155,132 | |
| 2,132,896 | Institution | 2.04% | 157,855,633 | |
| 1,193,732 | Institution | 1.14% | 88,348,105 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 7,866,587 | Institution | 7.54% | 582,206,104 | |
| 4,645,672 | Institution | 4.45% | 343,826,185 | |
| 2,132,896 | Institution | 2.04% | 157,855,633 | |
| 1,131,175 | Institution | 1.08% | 83,718,262 | |
| 1,000,885 | Institution | 0.96% | 74,075,499 | |
| 955,483 | Institution | 0.92% | 70,715,297 | |
| 954,330 | Institution | 0.91% | 70,629,963 | |
| 921,771 | Institution | 0.88% | 68,220,272 | |
| 805,724 | Institution | 0.77% | 59,631,633 | |
| 771,762 | Institution | 0.74% | 57,118,106 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,909,008 | Institution | 2.79% | 201,303,354 | |
| 2,368,570 | Institution | 2.27% | 175,297,866 | |
| 2,345,824 | Institution | 2.25% | 162,331,021 | |
| 1,340,731 | Institution | 1.29% | 92,778,585 | |
| 1,328,055 | Institution | 1.27% | 91,901,406 | |
| 854,262 | Institution | 0.82% | 63,223,931 | |
| 706,662 | Institution | 0.68% | 52,300,055 | |
| 564,159 | Institution | 0.54% | 41,753,408 | |
| 461,043 | Institution | 0.44% | 34,121,792 | |
| 349,855 | Institution | 0.34% | 24,209,966 |
FAQ
Who Owns Intra-Cellular Therapies (ITCI)?
According to the latest TipRanks data, approximately 19.79% of the company's stock is held by institutional investors, 32.26% is held by insiders, and 15.52% is held by retail investors.
What percentage of Intra-Cellular Therapies (ITCI) stock is held by institutional investors?
According to the latest TipRanks data, approximately 19.79% of Intra-Cellular Therapies (ITCI) stock is held by institutional investors.
What percentage of Intra-Cellular Therapies (ITCI) stock is held by retail investors?
According to the latest TipRanks data, approximately 15.52% of Intra-Cellular Therapies (ITCI) stock is held by retail investors.
Who owns the most shares of Intra-Cellular Therapies (ITCI)?
Vanguard owns the most shares of Intra-Cellular Therapies (ITCI).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.